STOCKHOLDERS’ EQUITY (Tables)
|
6 Months Ended |
Jul. 31, 2026 |
| Equity [Abstract] |
|
| Schedule of Common Stock Reserved for Issuance |
Common stock reserved for issuance as of July 31, 2026 and January 31, 2026 are presented as follows: | | | | | | | | | | | | | As of | | July 31, 2026 | | January 31, 2026 | | | | | | Stock options issued and outstanding | 31,865,065 | | | 39,283,485 | | | RSUs issued and outstanding | 21,737,477 | | | 9,311,201 | | | Shares of common stock available for future grants | 34,818,026 | | | 37,811,841 | | | Shares available for issuance under the 2025 Employee Stock Purchase Plan ("ESPP") | 7,213,399 | | | 5,000,000 | | | | | | | | | | | Total common stock reserved for issuance | 95,633,967 | | | 91,406,527 | |
|
| Schedule of Stock Option Activity |
The following table presents stock option activity for the six months ended July 31, 2026 (in thousands, except price per share, share and years data): | | | | | | | | | | | | | | | | | | | | | | | | | Number of Stock Options Outstanding | | Weighted-Average Exercise Price per Share | | Weighted- Average Remaining Contractual Life (Years) | | Aggregate Intrinsic Value | | Balance as of January 31, 2026 | 39,283,485 | | | $ | 13.91 | | | 5.7 | | $ | 55,743 | | | Granted | 1,010,099 | | | $ | 9.97 | | | | | | | Exercised | (7,804,467) | | | $ | 9.96 | | | | | $ | 76,941 | | | Cancelled/forfeited/expired | (624,052) | | | $ | 16.74 | | | | | | | Balance as of July 31, 2026 | 31,865,065 | | | $ | 14.70 | | | 6.1 | | $ | 379,830 | | | Vested and expected to vest as of July 31, 2026 | 31,865,065 | | | $ | 14.70 | | | 6.1 | | $ | 379,830 | | | Exercisable as of July 31, 2026 | 26,754,146 | | | $ | 14.12 | | | 5.7 | | $ | 334,447 | |
|
| Schedule of Restricted Stock Units Activity |
The following table presents the activity related to RSUs for the six months ended July 31, 2026: | | | | | | | | | | | | | Number of Shares Subject to RSUs | | Weighted-Average Grant Date Fair Value | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Unvested balance as of January 31, 2026 | 9,311,201 | | | $ | 22.23 | | | Granted | 16,497,425 | | | $ | 16.41 | | | Forfeited | (1,430,919) | | | $ | 20.15 | | | Vested | (2,640,230) | | | $ | 20.68 | | | Unvested and outstanding as of July 31, 2026 | 21,737,477 | | | $ | 18.14 | | | | | | | | | | | | | | | | | |
|
| Schedule of Stock-based Compensation Expense |
Stock-based compensation is included in the following components of expenses within the condensed consolidated statements of operations (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended July 31, | | Six Months Ended July 31, | | | | 2026 | | 2025 | | 2026 | | 2025 | | | | | | Cost of revenue | $ | 2,362 | | | $ | 855 | | | $ | 4,082 | | | $ | 1,902 | | | | | | | Research and development | 15,652 | | | 7,473 | | | 26,616 | | | 14,371 | | | | | | | Sales and marketing | 12,817 | | | 4,143 | | | 21,072 | | | 7,738 | | | | | | | General and administrative | 11,026 | | | 6,178 | | | 27,399 | | | 11,898 | | | | | | Total stock-based compensation expense, net of amounts capitalized | $ | 41,857 | | | $ | 18,649 | | | $ | 79,169 | | | $ | 35,909 | | | | | | | Capitalized stock-based compensation | 1,517 | | | 825 | | | 2,591 | | | 1,395 | | | | | | | Total stock-based compensation cost | $ | 43,374 | | | $ | 19,474 | | | $ | 81,760 | | | $ | 37,304 | | | | | |
|